Truss CBD USA, A HEXO Corp & Molson Coors Joint Venture, Launches Veryvell Sparkling CBD Water In Colorado

CANADA:  Truss CBD USA, a joint venture between HEXO Corp and Molson Coors Beverage Company, today announced the U.S. launch of VeryvellTM, a new line of non-alcoholic, sparkling CBD beverages, exclusively available in Colorado.

VeryvellTM is a hemp-derived, adaptogenic, sparkling CBD water now available to Colorado-based consumers in three flavours: Focus (Grapefruit Tarragon), Mind & Body (Strawberry Hibiscus) and Unwind (Blueberry Lavender). VeryvellTM is Powered by HEXOTM, the recognized quality and innovation behind award-winning products.

“We are excited to launch VeryvellTM in Colorado through Truss CBD USA, in collaboration with our partner, Molson Coors. Our joint venture with Molson Coors Canada saw Truss Beverage Brands become the number one choice for consumers in Canada and we are expecting similarly great results in the US.” said HEXO CEO and co-founder Sebastien St-Louis. “We have near-term plans to invest additional capital in the USA to support Truss CBD USA and to further execute on our Powered by HEXOTM strategy with other potential CPG partners, outside of beverages, with whom we are currently in ongoing negotiations.”

VeryvellTM is produced and distributed within Colorado state lines following the state’s established regulatory framework for hemp-derived CBD in food and beverages and is exclusively distributed by Coors Distributing Company. Truss CBD USA is distinct from Truss Beverages, Molson Coors and HEXO’s joint venture in Canada that focuses on non-alcoholic, cannabis-infused beverages.

Virginia Governor Northam Announces Industrial Hemp Company to Locate In Rockingham County

Governor Northam Announces Industrial Hemp Company to Locate in Rockingham County

VIRGINIA:  Governor Ralph Northam today announced that Shenandoah Valley Hemp, LLC dba Pure Shenandoah will invest nearly $3.3 million to establish an industrial hemp fiber processing and cannabidiol (CBD) oil extraction facility in the historic Casey Jones building in the Town of Elkton. The company will create 24 new jobs and has committed to purchasing 100 percent of its industrial hemp from Virginia growers, resulting in nearly $5 million in payments to Virginia farmers over the next three years. Pure Shenandoah will become the first participant in the Virginia’s Finest trademark program to source the hemp used in its products exclusively from the Commonwealth.

“Virginia’s industrial hemp industry continues to experience tremendous growth, creating a wealth of opportunity across our Commonwealth,” said Governor Northam. “Projects like this one are an important part of diversifying our economy and developing new markets for industrial hemp. Our administration remains committed to supporting growers and processors as we work to ensure this crop has a sustainable future in Virginia.”

Pure Shenandoah operates as a vertically integrated “seed to sale” company providing customers with safe and consistent hemp products of the highest quality. This includes strict regulatory control of crops, the application of certified good manufacturing practices, and complete traceability of each product back to the seed and farm from which it came.

“Pure Shenandoah is a great example of the many ways we are able to help innovative, agriculture-based companies grow and thrive in the Commonwealth,” said Secretary of Agriculture and Forestry Bettina Ring. “I am pleased to see continued job creation and investment in Virginia’s industrial hemp industry and excited for the new market opportunities the industry is creating for our farmers.”

“Industrial hemp is gaining momentum across the country, and we are excited for Virginia to be a player in this up-and-coming industry,” said Secretary of Commerce and Trade Brian Ball. “Pure Shenandoah will provide quality jobs and enable the Commonwealth’s hemp growers to source extraction and processing within Virginia, further benefiting our economy and agricultural ecosystem.”

As part of its strategic marketing efforts, Pure Shenandoah is a participating member of the Virginia’s Finest® program. Created more than 30 years ago with more than 500 participating companies, this program helps consumers know they are purchasing top-quality Virginia-produced specialty food products whenever they see the classic blue and red VA check mark logo.

“We are honored to receive these funds and to work with such influential state programs that are helping push the industrial hemp industry forward in the Commonwealth,” said Pure Shenandoah CEO Tanner Johnson. “With this support, we will continue to educate and provide safe and effective products to consumers. We are excited to do our part and help expand the future of industrial hemp and all of its potential.”

The Virginia Department of Agriculture and Consumer Services (VDACS) and Virginia Economic Development Partnership (VEDP) worked with Rockingham County and the Rockingham County Economic Development Authority to secure this project for the Commonwealth. Governor Northam approved a $50,000 grant from the Governor’s Agriculture and Forestry Industries Development (AFID) Fund for the project, which Rockingham County will match with local funds. Funding and services to support the company’s job creation will be provided through VEDP’s Virginia Jobs Investment Program.

“Rockingham County is pleased with the announcement of 24 new jobs and the investment of $3.3 million in eastern Rockingham County,” said Chairman of the Rockingham County Board of Supervisors Bill Kyger. “This is a new and exciting industry that offers a great opportunity to diversify the agriculture base of the county for the future.”

“We should never forget or take for granted Virginia’s tremendous agricultural heritage and its economic viability that continues to push Virginia forward,” said Senator Emmett Hanger. “I am pleased the AFID funds will further promote industrial hemp and that Pure Shenandoah is committed to exclusively sourcing Virginia agriculture products for this project. Of course, there is no better county to partner with on this funding than the number one agricultural county in the Commonwealth, Rockingham County. We are proud of our deep agricultural roots here in Virginia and this economic announcement adds yet another facet to our diverse agriculture operations.”

FDA Warns Companies Illegally Selling CBD Products

DISTRICT OF COLUMBIA:  The U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). All five warning letters address the illegal marketing of unapproved CBD products claiming to treat medical conditions. The warning letters include CBD products that are especially concerning from a public health perspective due to the route of administration, including nasal, ophthalmic and inhalation. In addition, they address violations relating to the addition of CBD to food, and the impermissible marketing of CBD products as dietary supplements. Two of the letters also address CBD products illegally marketed for pets, including a product for use in the eye.

“The FDA’s first priority is to protect the health and safety of Americans. Many questions remain regarding the science, safety, effectiveness and quality of products containing CBD,” said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. “We remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety. Meanwhile, we will continue to monitor and take action, as needed, against companies that unlawfully market their products — prioritizing those that pose the greatest risk of harm to the public.”

The warning letters were issued to:

The FDA has previously sent warning letters to other companies illegally selling unapproved CBD products that claimed to prevent, diagnose, mitigate, treat or cure various diseases, in violation of the FD&C Act. In some cases, there were further violations because CBD was added to food, and some of the products were impermissibly marketed as “dietary supplements.”

The products that are the subject of the letters issued today have not gone through the FDA drug approval process and therefore are considered unapproved new drugs. It is not known whether they are effective for the uses claimed in labeling, what an appropriate dose might be, how they could interact with FDA-approved drugs or other products or whether they have dangerous side effects or other safety concerns. In addition, the manufacturing process of these unapproved CBD-containing drug products has not been subject to FDA review as part of the human or animal drug approval processes, so it is not known what the manufacturing conditions of, or contaminant levels in these products may be.

Under the FD&C Act, any product intended to diagnose, cure, mitigate, treat or prevent a disease, and any product (other than a food) that is intended to affect the structure or function of the body of humans or animals, is a drug. New human and animal drugs must be approved by the FDA or conform to a “monograph” for a particular drug category, as established by FDA’s Over-the-Counter (OTC) Drug Review, before they can be legally marketed as drugs. CBD was not an ingredient considered under the OTC Drug Review.

The FDA has not approved any CBD products other than one prescription drug for the treatment of seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in human patients. CBD has not been approved as a food additive and does not meet the statutory definition of a dietary supplement.

The FDA has requested responses from the companies within 15 working days stating how they will address these issues, or providing their reasoning and supporting information as to why they think the products are not in violation of the law. Failure to adequately address the violations promptly may result in legal action, including product seizure and/or injunction.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

FTC Announces Crackdown On Deceptively Marketed CBD Products

Companies made unsupported claims that their oils, balms, gummies, coffee, and other goods could treat serious diseases such as cancer and diabetes

DISTRICT OF COLUMBIA: The Federal Trade Commission today announced the first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The FTC is taking action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others.

The FTC is requiring each of the companies, and individuals behind them, to stop making such unsupported health claims immediately, and several will pay monetary judgments to the agency. The orders settling the FTC’s complaints also bar the respondents from similar deceptive advertising in the future, and require that they have scientific evidence to support any health claims they make for CBD and other products.

“The six settlements announced today send a clear message to the burgeoning CBD industry: Don’t make spurious health claims that are unsupported by medical science,” said Andrew Smith, Director of the FTC’s Bureau of Consumer Protection. “Otherwise, don’t be surprised if you hear from the FTC.”

The crackdown, Operation CBDeceit, is part of the Commission’s ongoing effort to protect consumers from false, deceptive, and misleading health claims made in advertisements on websites and through social media companies such as Twitter.

Each case the FTC is announcing today is described below:

Bionatrol Health, LLC

According to the FTC’s complaint against Utah-based companies Bionatrol Health, LLC and Isle Revive, LLC, and two former managers and owners, since at least December 2019 the respondents sold a CBD oil to consumers on two websites. Among other things, the respondents allegedly claimed without substantiation that their CBD product is safe for all users, treats pain better than prescription medications like OxyContin, and prevents and treats age-related cognitive decline and chronic pain. The respondents also claimed, without scientific evidence, that CBD oil is “medically proven” to improve a variety of conditions, according to the FTC’s complaint. In addition, the FTC alleges the respondents deceived consumers who ordered one bottle of their CBD oil by changing the order to five bottles without consumers’ consent.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs without human clinical testing to substantiate the claims. It also requires competent and reliable scientific evidence for other health-related product claims, and prohibits the respondents from misrepresenting the cost of any good or service and from charging consumers without their express, informed consent. Finally, it requires the corporate respondents and individual respondent Marcello Torre to pay $20,000 to the FTC and to notify consumers of the Commission’s order.

Epichouse LLC (First Class Herbalist CBD)

According to the FTC’s complaint against Utah corporation Epichouse, LLC, which operated under several names, including First Class Herbalist, and the company’s founder and owner, John Le, since at least September 2019 the respondents sold several CBD products on their website, including oils, a pain-relief cream, coffee, and gummies.

Among other alleged unsupported claims, Epichouse and Le promoted CBD as safe for all users, able to treat pain better than prescription medications such as OxyContin, and able to prevent a wide range of serious conditions, including cancer, diabetes, and heart disease. In their advertising, they also falsely claimed that CBD is scientifically proven to improve many serious health conditions—including chronic pain and hypertension—and provide neurological benefit—such as preventing age-related cognitive decline—according to the FTC’s complaint.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, the order requires the respondents to pay $30,000 to the FTC and notify consumers of the Commission’s order.

CBD Meds, Inc.

According to the FTC’s complaint against CBD Meds, Inc.; G2 Hemp, Inc.; and Lawrence Moses, a/k/a Lawrence D. Moses, Jr., individually and as an officer of the corporate entities, the two companies advertised CBD oil on their website and on YouTube. In their ads, the FTC contends, the Winchester, California-based firms made a number of false or unsubstantiated claims, including that CBD effectively treats, prevents, or mitigates serious diseases and conditions like artery blockage, cancer, glaucoma, autism, and schizophrenia, among many others. The respondents also falsely represented that some of the efficacy claims were scientifically proven or that the U.S. government has confirmed the health benefits of CBD.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. More broadly, it requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, the order requires the respondents to notify consumers of the Commission’s order.

HempmeCBD

According to the FTC’s complaint against EasyButter, LLC, also d/b/a HempmeCBD, and its owner and officer Michael Solomon, since at least January 2018, the respondents have sold CBD products on their website, including CBD-infused shea butter, gummies, lozenges, honey sticks, vape pens, and oils. The complaint alleges that HempmeCBD claimed its CBD products could treat or cure serious ailments like cancer-related symptoms, substance abuse, and AIDS. The complaint alleges HempmeCBD lacked the scientific substantiation for such health claims and falsely claimed to have studies showing CBD is effective at treating autism.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It also requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, it requires the respondents to pay the FTC $36,254 and to notify consumers of the Commission’s order.

Reef Industries, Inc.

According to the FTC’s complaint against California-based Reef Industries, Inc.; Cannatera, Inc.; AndHemp, Ltd., and the companies’ three principals, the respondents have sold a variety of CBD products directly to consumers on their website and Twitter accounts since at least January 2019 and misrepresented the health benefits of CBD. The FTC alleges that the respondents made unsubstantiated claims that CBD can prevent, cure, mitigate, or treat diseases and serious health conditions, including Alzheimer’s disease, arthritis, autoimmune disease, and irritable bowel syndrome. The complaint also alleges the respondents falsely claimed that studies or scientific research prove that CBD is effective at treating, curing, or mitigating these diseases and conditions.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. More broadly, it requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, it requires them to pay the FTC $85,000 and notify consumers of the Commission’s order.

Steves Distributing, LLC

According to the FTC’s complaint against Steves Distributing, LLC, d/b/a Steve’s Goods; and the company’s CEO Steven Taylor Schultheis, since beginning operations in 2018, the respondents have sold a variety of products containing both CBD and cannabigerol (CBG), which, like CBD, is a non-psychoactive compound derived from hemp. The company advertises its CBD and CBG products, including tinctures, gummies, capsules, topical balms, suppositories, bath balms, and coffee, on its website and through social media companies like Twitter.

The FTC alleges that the respondents claimed, without adequate substantiation, that their CBD and CBG products are effective alternatives to prescription medications and treat a wide range of diseases and serious health conditions, including Alzheimer’s disease, cancer, and diabetes. The complaint also alleges the respondents falsely claimed that their CBD and CBG products have antibacterial properties, prevent or reduce the risk of heart attacks, strokes, and other diseases, and that certain of these claims were supported by scientific evidence.

The proposed administrative order settling the FTC’s charges prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. More broadly, it requires them to have competent and reliable scientific evidence when making any other health-related product claims. Finally, it requires the respondents to pay the FTC $75,000 and notify consumers of the Commission’s order.

The Commission votes approving each of the six administrative complaints and proposed consent orders were 5-0, with Commissioner Rohit Chopra and Commissioner Christine S. Wilson issuing separate, concurring statements. A complete list of respondents can be found in the complaint for each respective case.

The FTC will publish a description of the consent agreement package in the Federal Register soon. The agreement will be subject to public comment for 30 days after publication in the Federal Register after which the Commission will decide whether to make the proposed consent order final. Instructions for filing comments will appear in the published notice. Once processed, comments will be posted on Regulations.gov.

NOTE: The Commission issues an administrative complaint when it has “reason to believe” that the law has been or is being violated, and it appears to the Commission that a proceeding is in the public interest. When the Commission issues a consent order on a final basis, it carries the force of law with respect to future actions. Each violation of such an order may result in a civil penalty of up to $43,280.

Minnesota: Congressman Peterson Joins Smith, Craig and McCollum To Urge Federal Agencies To Clarify Hemp Rules

MINNESOTA: Representative Collin Peterson today jointed U.S. Senator Tina Smith (D-Minn.) and U.S. Representatives Angie Craig (D-MN 2), and Betty McCollum (D-MN 4) in calling on the leaders of four federal agencies to streamline hemp rules. Currently, contradictory federal guidelines are leading to uncertainty in the market and preventing Minnesota farmers and Tribes from fully reaping the economic benefits of growing hemp.

“The bipartisan 2018 Farm Bill legalized hemp in order to create economic opportunities for farmers. Minnesota farmers appreciate the United States Department of Agriculture’s (USDA) efforts in implementing the Interim Rule on Establishment of a Domestic Hemp Production Program. However, despite the Interim Rule there are still hurdles in place for Minnesota farmers to fully realize the economic benefits of growing hemp,” wrote the lawmakers in their letter to the United States Department of Agriculture (USDA), the Office of Management and Budget (OMB), the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).

Sen. Smith and Reps. Craig, McCollum and Peterson go on to identify some of the inconsistencies that need to be addressed: “The federal regulatory framework has proven to be inconsistent. For example, the USDA’s rule stated that farmers will be held accountable – facing possible revoking of their licenses – if their crops test above a .5 percent THC level three times in a five year period. Despite this somewhat onerous and arbitrary level, the Drug Enforcement Agency (DEA) instituted their own rule saying that exceeding .3 percent THC level deems the crop a controlled substance.

The burdensome competing rules don’t allow for remediation if the crop tests above the deemed inappropriate levels. Farmers should not be penalized for plants that they intended to grow as hemp, but for any number of reasons, the final THC numbers exceeded the arbitrary 0.3% THC level.  At the same time, the Food and Drug Administration (FDA) guidance on CBD is still pending at the Office of Management and Budget (OMB), which adds even more uncertainty to the marketplace.”

NIHC Receives USDA MAP Funding for International Research And Promotion Of Hemp

DISTRICT OF COLUMBIA: National Industrial Hemp Council today announced it received $200,000 in U.S. Department of Agricultural (USDA) Market Access Program (MAP) funding to support export market development of industrial hemp.

“We are grateful for USDA confidence and the recognition of NIHC as the industry leader in industrial hemp trade and marketing,” said Kevin Latner, NIHC’s Senior Vice President for Trade and Marketing who will be responsible for implementing the program.  “Today’s announcement makes NIHC a trusted partner to USDA for hemp fiber, feed, food and CBD companies looking to break down trade barriers in markets overseas.”

MAP funds are administered through USDA’s Foreign Agricultural Service (FAS). Through the MAP program, FAS partners with U.S. agricultural trade associations, cooperatives, state regional trade groups and small businesses to share the costs of overseas marketing and promotional activities that help build commercial export markets for U.S. agricultural products and commodities. These funds can be used for facilitating trade missions and meeting with industry stakeholders and government regulators overseas.

NIHC programs will focus on Europe and China and include market research, trade policy and trade facilitation.  The global industrial hemp and products market was estimated at $11.1 billion in retail sales in 2019.  With an annual growth rate of 52 percent, driven by continued strength in textiles, food and industrial uses and hemp-derived cannabidiol (CBD), the global market is forecast to be worth $89 billion by 2025.

Hemp for industrial use, textile and CBD market is expected to quickly expand and be the primary driver of global industry growth.  By 2021, the global trade of hemp is forecast $8.1 billion across all markets, representing a three-year compound annual growth rate (CAGR) of 83 percent.  EuropeChina, and Canada are currently the primary sources of industrial hemp.  With the passage of the 2018 Farm Bill, the U.S. has become the world’s third largest producer of industrial hemp.

Europe has rapidly developed a robust hemp and CBD market.  Europe is also a strong producer of industrial use hemp products with $424 million in industrial product sales. China has led global markets in textiles with almost 80 percent of the $1.7 billion hemp textile market, in 2019.

In addition, National Industrial Hemp Council members will now have unprecedented access to United States trade negotiators; foreign government counterparts; and a network of international hemp industry association counterparts. Foreign governments understand that NIHC is now supported by the U.S. government and represents U.S. industry interests.

Market Access Program funds can be used by NIHC throughout the world to support market access and trade policy work, international trade promotion including supporting business-to-business facilitation, and consumer and brand marketing.

MAP funds for 2021 will be administered to NIHC through the Food Export Association of the Midwest USA.    

“We’re extremely confident and trust that NIHC will represent the best interests of U.S. industrial hemp abroad. We’re excited to be working with them as part of the USDA cooperator community,” said Tim Hamilton, Executive Director of Food Export Association of the Midwest USA.

Canopy Growth Expands Beverage Portfolio with Launch of First CBD-Infused Beverage Line Quatreau

New Product Line Features A Range of Naturally Flavoured Cannabis-Infused Sparkling Waters In Both CBD-only and Balanced (CBD + THC) Offerings

CANADA: Canopy Growth, a world-leading diversified cannabis, hemp, and cannabis device company, today announced the launch of Quatreau, a new line of premium CBD-infused beverages. The naturally flavoured sparkling waters are Canopy Growth’s first CBD-infused drinks, with both CBD-only and “balanced” (CBD + THC) offerings available in Canada. Launched on the heels of incredible growth in sales from the Company’s THC-infused beverages, released earlier this year, Canopy Growth is uniquely positioned to win market share in the CBD beverage space.

“We are proud to debut our first CBD-infused beverage brand in Canada, where we already lead the cannabis-infused beverage category, at a price point that delivers both quality and value to consumers,” said David Klein, CEO, Canopy Growth.  “We created Quatreau as an alternative to sugary, caffeinated beverages or even alcohol. With both CBD-only and “balanced” (CBD + THC) offerings in four natural  flavours, Quatreau meets the needs of discerning cannabis consumers.”

Canopy Growth plans to continue developing category leading brands that are driven by consumer insights, product-focused, with industry leading scientific formulation. Building on the successful launch and strong sales of THC-infused cannabis beverage brands Tweed, Houseplant and Deep Space, Canopy is poised to continue leading the cannabis space with the launch of Quatreau CBD-infused sparkling water, a consistent CBD product in a beverage format that is familiar to consumers.

Quatreau’s naturally flavoured Canadian product line includes four offerings named:

  • Quatreau Cucumber + Mint (contains 20 mg of CBD and < 1 mg of THC)
  • Quatreau Passion Fruit + Guava (contains 20 mg of CBD and < 1 mg of THC)
  • Quatreau Ginger + Lime (contains 2 mg of CBD and 2 mg of THC)
  • Quatreau Blueberry + Açai (contains 2 mg of CBD and 2 mg of THC)

For more information, visit quatreauwater.com

The Hemp Industry: Where Are We Going? 

By Steven Gluckstern
Chair and CEO, Santa Fe Farms

It’s difficult to predict where the hemp industry will go over the next five years and how it will develop as it is only been just over 22 months since the farm bill of 2018 was passed legalizing hemp for transport across state lines. This legislation opened up an entire new industry for CBD and other hemp related products. What we do know, is that hemp is an extraordinary plant and the industry, although nascent, will have a profound impact both economically and environmentally in both the US and abroad.

What we learned in the first two years of the legalized hemp industry is now that everyone rushed into cultivation, farming may not be the most profitable sector. The primary lesson learned for most people is that when you partner with Mother Nature, she is fickle and almost always wins. Furthermore, unlike corn, soy, and other US agricultural products, the plant needs to go through a transformational process to make it usable for downstream products. Thought of as the narrow center of the hourglass or “chokepoint” of the industry, the plant needs to be processed and/or extracted to be usable for anything other than smokable flower.

While much of the industry is now focused on CBD and other phyto-cannabinoid products (the base of the hourglass), our vision at Santa Fe Farms is much broader and includes not only cultivation, and processing, but industrial hemp for building materials, plastics, paper, and other manufactured goods as well as our own phyto-cannabinoid products. Additionally, we are discovering that carbon-based derivatives obtained through pyrolysis will drive further business in ways we are just beginning to understand and that could have significant impact on both renewable energy and environmental sustainability.

We also believe there is significant opportunity for technology; because this is a nascent industry, the visibility of the hemp supply chain is almost nonexistent. Studying the data is almost impossible but as advanced technologies such as blockchain become “mainstream”, we will soon see efficiencies in cultivation, harvesting, processing, and innovation. We have always thought there was significant opportunity for software as it relates to the hemp supply chain, and with experienced partners have begun investing significant resources to create an industry agnostic “Supply Chain as a Service” platform.

When we started at Santa Fe Farms, we initially thought only about cultivation, but quickly realized that one should make multiple bets to maximize profit one likely had to allocate capital to all parts of the business from seed genetics to retail sale. In the short-term, we believe that prices will stabilize, people will leave the industry (by choice and necessity) and that prices will rise as demand increases.

More interesting however is looking out ten years. As we face the “hemp future,” there is a tremendous lack of visibility of regulation. We can hopefully drive regulation from within by creating products and SOPs that adhere to high quality standards. No one knows what future regulation will look like as it is clearly, at best, a work in progress. However, it represents a place where we can come together as an industry to create policy change, social justice and educational platforms.

Kristen Bell Launches Happy Dance CBD Brand

CANADA: Cronos Group Inc. announced the launch of Happy Dance™, a new, clean, simple CBD skincare brand, co-founded with actress and New York Times best-selling author Kristen Bell. Happy Dance launches with a trio of high-quality, cruelty-free and vegan bath and body care products.

The new Happy Dance collection features a body butter, a coconut melt and a bath bomb, all formulated with Kristen Bell’s favorite clean ingredients and high-quality CBD from full-spectrum hemp extract. These multi-purpose products are infused with delightful blends of plant-based oils and butters in enjoyable textures that are effortlessly easy-to-use. The ultimate head-to-toe body treats, Happy Dance products are perfectly suited for the CBD enthusiast or for someone experiencing CBD for the first time.

“I discovered CBD through the Lord Jones™ brand in 2017 and was blown away by its quality, integrity and consistency. As a working mom, I turned to CBD skincare as a way to turn down the volume of my life and CBD products have since become an essential part of my self-care routine,” said Kristen Bell. “I was inspired to create a line of high-quality, affordable CBD bath and body care products that would reach a wide audience. Having been involved in all aspects of bringing this new brand to life, from the formulations to the packaging, I couldn’t be happier to launch Happy Dance today.”

“After years as a working actress, Kristen Bell understands the importance of taking care of your skin,” said Summer Frein, U.S. General Manager, Cronos Group. “Her passion for the category started with her personal and professional experience as a skincare ambassador and she has since become someone who people look to for personal care advice and expertise.”

The Happy Dance brand is the epitome of good, clean, fun. The full-spectrum hemp-derived CBD product collection launching today features:

  • Happy Dance Whipped Body Butter (200mg CBD) – $30
  • Happy Dance Head-to-Toe Coconut Melt (225mg CBD) – $25
  • Happy Dance Stress Away Bath Bomb (60mg CBD) – $15

“We feel fortunate to be working with someone as authentic, caring and kind as Kristen,” said Kurt Schmidt, President and Chief Executive Officer, Cronos Group. “We have always been committed to improving people’s lives with breakthrough cannabinoid products, which is why we’re incredibly excited to launch an accessible, purpose-driven brand with Kristen Bell, someone we know consumers trust for her integrity and relatability.”

Happy Dance’s commitment to self-care extends not only to its products, but to the community it serves. One percent of profits from sales on the Happy Dance website will benefit A New Way of Life Re-Entry Project, a Black-owned LA-based organization that provides housing, case management, pro bono legal services, advocacy and leadership development for women rebuilding their lives after prison.

“It was essential to me that Happy Dance be a purpose-driven brand that challenged the traditional notion of self-care,” said Kristen Bell. “And when I care for myself, I can better care for others. Happy Dance’s commitment to care extends to those who need it most, which is why we are honored to be partnering with A New Way of Life Re-Entry Project.”

Happy Dance products undergo extensive third-party testing, are vegan and cruelty-free and tested for heavy metals, microbiological contaminants, residual solvents and pesticides. Each product formula is evaluated through clinical testing according to cosmetic industry standards. Every product also features traceable lot codes allowing customers to review product Certificates of Analysis (COA).

For more information, or to purchase Happy Dance products, visit www.doahappydance.com or @happydance.

Anavii Market Offers Brand New Line Of Martha Stewart CBD Products

​Anavii Market, a premier online retailer of verified CBD oil, today announced the unveiling of a much-anticipated brand of Martha Stewart CBD. The new collection consists of six unique hemp products, including CBD tinctures, gummies and softgels, all developed and curated by Martha Stewart herself in partnership with Canopy Growth Corporation.

This is the first-ever CBD product launch by the lifestyle enthusiast in collaboration with Canopy Growth, which is a world-renowned CBD company.

Anavii Market is thrilled to team up with Canopy Growth in selling Martha Stewart’s brand new collection of CBD oil.

“Bringing quality and pure hemp wellness products to America is our mission at Anavii Market, and we are happy to partner with Martha and Canopy to help spread the good news about CBD to their networks,” said Jason Amatucci, co-founder of Anavii Market.

Starting today, customers are able to enjoy the exciting new flavors that Martha Stewart specially designed herself. This new range of products incorporates the most flavorful side of CBD, as well as Martha’s drive to create only the best quality products made from the purest hemp.

Buyers are welcomed to try Martha Stewart CBD Tincture, which is a concentrated blend of CBD oil extracted from the highest quality hemp. CBD tinctures are easy to use and designed to distribute a specific amount of CBD per serving. Each serving contains 25 mL of two exciting, citrusy flavors. These include blood orange and Meyer lemon.

Anavii Market is also offering a delicious assortment of Martha Stewart CBD Gummies. Infused with 99% pure CBD isolate per gummy, these tasty, chewable treats come in two fruit medleys of berry and citrus, and are the perfect size to carry anywhere you go.

Made with only the finest ingredients, Martha Stewart CBD Softgels offer the best quality and consistency of CBD oil on the market. Each softgel contains 25mg of CBD and is made with non-GMO, coconut-derived MCT oil and pure-hemp derived CBD isolate.

All Martha Stewart CBD products have been rigorously lab-tested to ensure that the products contain zero heavy metals, pesticides, solvents and other toxins.

Consumers can purchase each Martha Stewart CBD product through Anavii Market’s online store and get a 20% off discount for a limited time. For more information and updates about the Martha Stewart CBD product launch, follow the Anavii Market blog today.